Chapter: Risk Assessment in ASCVD

1. Evaluate individuals for an atherosclerotic cardiovascular disease (ASCVD) risk assessment using a validated risk prediction tool.
2. Distinguish risk factors for ASCVD used in validated risk prediction tools.
3. Evaluate the advantages and disadvantages of the Framingham Risk Score.
4. Evaluate the advantages and disadvantages of the pooled cohort equations risk score.
5. Assess the clinical utility of other validated risk prediction tools.
6. Identify those individuals who should undergo an assessment for ASCVD using additional testing. 

Chapter: New Therapies to Treat Dyslipidemia

1. Assess cardiovascular risk conferred by lipids and lipoproteins.
2. Justify the use of individualized lipid targets based on current evidence and guidelines.
3. Develop a comprehensive plan to optimize lipid-lowering therapy.
4. Evaluate the appropriate use of emerging lipid-lowering therapies. 

Chapter: Nocebo Effects of Statins and Other ASCVD Risk Reduction Therapies

1. Distinguish between placebo, nocebo, and drucebo effects and identify which medications have drucebo effects.
2. Evaluate patients for drucebo effects related to cardiovascular therapies.
3. Demonstrate how statin-associated muscle symptoms impact patient care.
4. Devise a strategy to overcome non-evidence-based advice related to drucebo effects. 

Case Series: Fish Oil Controversies

1. Evaluate the historical data on which consensus recommendations for the use of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are based.
2. Analyze the clinical controversies surrounding the use of omega-3 fatty acids (O3FAs) to reduce cardiovascular (CV) risk.
3. Assess the clinical usefulness of icosapent ethyl in the contemporary management of atherosclerotic CV disease (ASCVD) risk reduction.
4. Evaluate the influence O3FA/EPA/DHA and placebo formulations may have had on outcomes observed in randomized clinical trials.
5. Distinguish patient-specific data and identify risk factors and/or comorbidities that may place the patient at higher risk of adverse effects related to the use of fish oil and its derivatives.
6. Develop a comprehensive plan for managing ASCVD risk with O3FAs in appropriate individuals.  

Chapter: Evolving Antiplatelet Regimens in Atherosclerotic Cardiovascular Disease

1. Distinguish patient and procedural characteristics that influence thrombosis and bleeding risk in patients with atherosclerotic cardiovascular disease (ASCVD) requiring antiplatelet therapy.
2. Assess drug-eluting stent characteristics that affect thrombosis risk in patients with ASCVD.
3. Evaluate the strengths and weaknesses of pharmacogenomic-guided strategies in determining antiplatelet therapy.
4. Design an antiplatelet therapy plan that balances thrombosis and bleeding risk in patients with ASCVD 

Chapter: Evolution of β-blockers in ASCVD

1. Distinguish between β-blockers on the basis of receptor specificity.
2. Evaluate the risks and benefits of β-blocker use in patients at risk of atherosclerotic cardiovascular disease (ASCVD).
3. Justify the role for β-blockers in patients with chronic coronary disease and acute coronary syndrome.
4. Design an appropriate antihypertensive regimen in patients with peripheral artery disease and stroke.
5. Justify deprescribing β-blockers in patients at risk of or with ASCVD.  

Case Series: Lower Extremity Peripheral Arterial Disease

1. Assess at-risk patients for signs or symptoms of lower extremity peripheral artery disease (PAD)
2. Justify the need for atherosclerotic risk-reduction strategies in a person with PAD
3. Evaluate the risk versus benefit of antithrombotic therapy for a patient with asymptomatic PAD
4. Design an antithrombotic treatment regimen for a patient with symptomatic PAD
5. Develop an antithrombotic treatment regimen for a patient who underwent revascularization for PAD 

Case Series: Refractory Angina

1. Based on epidemiologic data, evaluate the prognosis of patients with refractory angina (RA).
2. Use patient-specific data to distinguish among the pathophysiology and the various phenotypes of RA.
3. Develop a patient-specific treatment plan that incorporates a patient's pathophysiology and co-morbidities.
4. Evaluate patients for risk factor modifications and nonpharmacologic treatments for RA.
5. Justify the role of the pharmacist on a specialized team or clinic for the management of RA. 

Case Series: Biostatistical and Study Design Application in ASCVD

1. Assess the strength of evidence for a study according to its design.
2. Assess data and variable types, including how they are summarized in studies.
3. Evaluate the efficacy or safety of an intervention by interpreting the statistical comparison of summarized data points between treatment arms.
4. Apply study results to clinical decisions in practice using biostatistics and study design principles.